DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for red-green color blindness — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRed-green color blindness maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for red-green color blindness is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cannabinoid receptor 1 (CNR1) — CNR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5z,8z,11z,13s,14zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8GHV · 2.8 Å · ligand (5Z,8Z,11Z,13S,14Z)-N-[(2R)-1-hydroxypropan-2-yl]-13-methylicosa-5,8,11,14-tetraenamide (ZI5). Experimental structure, not a prediction.
What the evidence adds up to
Red-green colour blindness is linked to the X-chromosome gene array that normally contains a single red pigment gene followed by one or more green pigment genes. Unequal recombination can delete genes or create red-green hybrid genes, and because only the two most proximal genes in the array are expressed in the retina, the severity of the defect roughly corresponds to the difference in absorption maxima of the photopigments encoded by those first two genes. A single amino acid polymorphism (Ser180Ala) in the red pigment accounts for subtle normal variation and also influences the severity of deficiency. Blue cone monochromacy, a rare disorder involving absence of red and green cone function, is caused either by deletion of a regulatory region or by mutations that inactivate both pigment genes. Total colour blindness, another rare condition, involves complete absence of all cone function and has been linked to mutations in genes encoding cone-specific cation channel subunits and transducin.
Adaptive optics retinal imaging has revealed that some forms of red-green dichromacy are caused not by a missing photopigment but by the actual loss of the entire corresponding class of cone photoreceptor cells. This mechanism had previously been discounted. Remarkably, losing one-third of the cones does not impair any aspect of vision other than colour. This finding was confirmed in a 2004 study using adaptive optics.
A 2025 study of three patients with CNGA3 achromatopsia treated with gene therapy found that clinical improvement was subtle. Diffusion tensor imaging showed no significant differences from normally sighted controls in optic tract and radiation integrity before treatment. A reduction in fibre integrity was observed in occipitocallosal fibres, and this showed some normalisation after treatment, but intersubject variability was evident. The authors concluded that primary visual pathways are comparable to those of healthy individuals and that fibre integrity is probably not an obstacle for recovery. They noted that patients did not experience a sudden eureka moment of being able to perceive the full spectrum of colours.
A 2024 review article discusses gene therapy, pharmacological interventions, and visual aids as treatment approaches for colour blindness, and mentions promising results from clinical trials as well as ongoing challenges. However, the review does not provide specific numbers for response rates or survival. What remains missing are large, controlled trials with objective colour vision endpoints, validated patient stratification by genotype and photoreceptor loss pattern, and funding to move beyond the subtle improvements seen in small gene therapy studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Proceedings of the National Academy of Sciences · 2004 · 254 citations · open access
Functional photoreceptor loss revealed with adaptive optics: An alternate cause of color blindness
AbstractThere is enormous variation in the X-linked L/M (long/middle wavelength sensitive) gene array underlying "normal" color vision in humans. This variability has been shown to underlie individual variation in color matching behavior. Recently, red-green color blindness has also been shown to be associated with distinctly different genotypes. This has opened the possibility that there may be important phenotypic differences within classically defined groups of color blind individuals. Here, adaptive optics retinal imaging has revealed a mechanism for producing dichromatic color vision in which the expression of a mutant cone photopigment gene leads to the loss of the entire corresponding class of cone photoreceptor cells. Previously, the theory that common forms of inherited color blindness could be caused by the loss of photoreceptor cells had been discounted. We confirm that remarkably, this loss of one-third of the cones does not impair any aspect of vision other than color.
Ophthalmic Wearable Devices for Color Blindness Management
AbstractAbstract Color vision deficiency (CVD) or color blindness is an ocular disorder that hinders the patients from distinguishing shades of certain colors. Color blind patients are often not considered for critical occupations (e.g., military, police) and cannot differentiate colors in public places or media (i.e., watching TV). The most common form of color blindness is red‐green, which is a result of either a missing or defective red or green photoreceptor cone. Since no cure for this disorder exists, sufferers opt for methods to enhance their color perception. The products and methods that have been developed to aid CVD patients are discussed. These technologies include contemporary work on gene therapy, tinted glasses, lenses, optoelectronic glasses, and advanced features developed on smartphones and computers. Among these wearables, tinted glasses, developed by companies such as Enchroma, are the most widely used by CVD patients.
Developments in ophthalmology · 2003 · 22 citations
Genetics of Color Vision Deficiencies
AbstractThe normal X-chromosome-linked color vision gene array is composed of a single red pigment gene followed by one or more green pigment genes. The high degree of homology between these genes predisposed them to unequal recombination, leading to gene deletions or the formation of red-green hybrid genes that explain the majority of the common red-green color vision deficiencies. Gene expression studies suggest that only the two most proximal genes of the array are expressed in the retina. The severity of the color vision defect is roughly related to the difference in absorption maxima of the photopigments encoded by the first two genes of the array. A single amino acid polymorphism (Ser180Ala) in the red pigment accounts for the subtle difference in normal color vision and influences the severity of color vision deficiency. Blue cone monochromacy is a rare disorder that involves absence of red and green cone function. It is caused either by deletion of a critical region that regulates expression of the red/green gene array, or by mutations that inactivate the red and green pigment genes. Total color blindness is another rare disease that involves complete absence of all cone function. A number of mutations in the genes encoding the cone-specific alpha- and beta-subunits of the cation channel and the alpha-subunit of transducin have been implicated in this disorder.
Frontiers in Neuroscience · 2024 · 13 citations · open access
Dyschromatopsia: a comprehensive analysis of mechanisms and cutting-edge treatments for color vision deficiency
AbstractColor blindness is a retinal disease that mainly manifests as a color vision disorder, characterized by achromatopsia, red-green color blindness, and blue-yellow color blindness. With the development of technology and progress in theory, extensive research has been conducted on the genetic basis of color blindness, and various approaches have been explored for its treatment. This article aims to provide a comprehensive review of recent advances in understanding the pathological mechanism, clinical symptoms, and treatment options for color blindness. Additionally, we discuss the various treatment approaches that have been developed to address color blindness, including gene therapy, pharmacological interventions, and visual aids. Furthermore, we highlight the promising results from clinical trials of these treatments, as well as the ongoing challenges that must be addressed to achieve effective and long-lasting therapeutic outcomes. Overall, this review provides valuable insights into the current state of research on color blindness, with the intention of informing further investigation and development of effective treatments for this disease.
A SINGLE JUDGMENT TEST FOR RED-GREEN DISCRIMINATION
AbstractInstitute of Ophthalmology New York, New York *This paper is part of a symposium on Color Blindness and Color Blindness Tests arranged for the March 4–6, 1943 meeting of the Optical Society of America, by the Inter-Society Color Council. From the Journal of the Optical Society of America. Vol. 33, No. 9, pp. 512–514. 1943. †Chairman of the Inter-Society Color Council Committee on Development of a Red-Green Discrimination Test.
AbstractOriginally published in 1925, this book embodies the results of research on red-green colour-blind subjects, supplemented by brief accounts of blue-yellow, total, and acquired colour-blindness to complete the description of the different forms of the defect. After a historical survey of previous work by such men as Dalton, Helmholtz, Rayleigh, Edridge-Green and others, the author deals with the most important theories of colour-blindness, and with a description of the tests and a discussion of their results.
Visual Tract Integrity Before and After Gene Therapy in Congenital Achromatopsia
AbstractPurpose: CNGA3 achromatopsia is a rare hereditary syndrome caused by dysfunction of cone photoreceptors. Visual information is therefore obtained only by rod photoreceptors, resulting in low acuity, photoaversion, and color blindness. Trials using gene therapy have been initiated recently, in which clinical improvement was subtle. Methods: To explain this suboptimal outcome, we used diffusion tensor imaging to assess visual pathway integrity in 3 CNGA3 achromatopsia patients before and after gene therapy, and compared them with 16 normally sighted adults. Results: No significant differences from normal subjects in optic tract and radiation were detected. Fiber integrity reduction was observed in the occipitocallosal fibers. These differences showed some normalization after treatment, but intersubject variability was evident. Specifically, the observed changes were related to radial diffusivities, reflecting fiber myelination or glial cell alterations. Conclusions: Despite the fundamental role of cone photoreceptors in human sight, primary visual pathways in patients are comparable with those of healthy individuals and thereby fiber integrity is probably not an obstacle for recovery. Preliminary results suggest that the splenial fibers are less cohesive in naïve patients and regain some integrity after treatment. These findings add to previous reports on this rare population and suggest that novel information is processed within the visual cortex after treatment. Translational Relevance: Patients with complete color blindness were treated using a novel gene augmentation therapy. Unfortunately, the patients did not experience a sudden eureka moment of being able to perceive the full spectrum of colors. In this study, we rule out fiber disintegration as the cause of their limited recovery.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
